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In this study, immunoglobulin variable (Ig V) region genes,
c-myc re-arrangement and sequence and p53 status were
analyzed in clones derived from a Burkitt’s lymphoma cell
line (LAM) in which it was previously demonstrated that
Epstein-Barr virus (EBV) infection occurred late during lym-
phomagenesis. Such evidence was based on the finding that 2
groups of cellular clones, characterized by the same c-myc
re-arrangement but different EBV-fused termini, were ob-
tained from the LAM cell line. The Ig V gene sequences were
identical for the 2 groups of clones with different EBV-fused
termini. The Ig variable heavy (VH) gene sequence displayed
a substantial accumulation of point mutations (but no intra-
clonal diversification), whereas the productive Ig V lambda
(Vl) gene sequence was virtually unmutated. Studies on the
Ig V kappa (Vk) locus suggested a receptor revision event
(with a switch from k to l chain production) prior to EBV
infection. Likewise, it was determined that the mutations
observed in both p53 alleles and in the re-arranged c-myc
gene occurred before EBV infection. Based on these findings,
we present a model for the various steps of lymphomagen-
esis. It is proposed that stimulation by an antigen or a supe-
rantigen initially favored the clonal expansion and accumula-
tion of other cytogenetic changes, including those involved in
receptor editing. These events occurred prior to or during
the germinal center (GC) phase of B-cell maturation. There-
after, possibly upon exit of the cells from the GC, EBV infec-
tion occurred, further promoting lymphomagenesis. Int.
J. Cancer 88:744–750, 2000.
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Burkitt’s lymphoma (BL) is a high-grade lymphoma of which
there are 2 main variants, known as endemic (e) BL and sporadic
(s) BL (Magrath, 1990). Although they share a number of cyto-
genetic features, eBL and sBL are distinguished by their clinical
presentation and the presence of the Epstein-Barr virus (EBV)
genome, which is harbored in the vast majority of eBL and absent
in most sBL cases. In addition, eBL primarily affects children and
young adults of particular geographical areas (Magrath, 1990).
Patients with AIDS have a high frequency of BL, and in this
setting, it resembles sBL except that the EBV genome is found
more frequently (in up to 50% of cases, depending on different
reports) (Gaidano and Dalla-Favera, 1995).
All BL cases are characterized by chromosomal translocation of
the c-myc oncogene, which moves from its normal location on
chromosome 8 to chromosome 14 (Dalla-Favera et al., 1982) or,
less frequently, to chromosome 2 or 22 (Croce et al., 1983).
Because of this translocation, c-myc becomes juxtaposed with the
regulatory regions of Ig genes and is generally over-expressed.
However, although this event must be considered a conditio sine
qua non, the sole c-myc translocation appears to be insufficient to
cause fully neoplastic transformation of the cells in vivo. Other
cytogenetic changes commonly found in BL include mutations of
c-myc (Bhatia et al., 1994) and p53 (Gaidano et al., 1991) and
changes in the 59-untranslated region of bcl-6 (Capello et al.,
1997). Moreover, the presence of the EBV genome may contribute
to malignant transformation. Although the relative pathogenetic
role of these factors is not fully understood, some information
could be obtained by ascertaining the relative timing of these
events. Our study deals with the timing of these transforming
events in a special case of an AIDS-related BL (Roncella et al.,
1993).
We previously showed that primary samples obtained from the
bone marrow and the peripheral blood of this BL as well as the cell
lines and cell clones derived from them displayed 2 different
EBV-fused termini. The 2 groups of malignant cells, however, had
the same VDJ and c-myc re-arrangements. Based on this observa-
tion, we suggested that EBV infection was a late event in lym-
phomagenesis. Here, we investigated the timing and the features of
other genetic changes that characterized the malignant cells. Our
analysis disclosed a complex series of re-arrangements at Ig loci
that might have occurred in the germinal center (GC) during
antigen stimulation. Our findings suggest that some of the genetic
alterations seen in BL may be generated during the GC reaction.
MATERIAL AND METHODS
Patients and cell lines
The patient LAM has been described previously (Roncella et al.,
1993). Spontaneous cell lines were obtained, after in vitro culture,
from both the peripheral blood mononuclear cells (PB-LAM) and
from the bone marrow (BM-LAM). These cell lines were cloned
by limiting dilution, and the following clones were obtained and
studied: BM-C4, BM-D4, BM-C4S1, BM-C4S2, BM-H4 (from
BM-LAM), PB-C3S4, PB-F8, PB-F3, PB-D8 and PB-B2.1 (from
PB-LAM). These clones expressed surface IgM/l and showed the
typical phenotype of BL with expression of CD10 and CD38 and
lack of CD39 and CD23. LAM-K was obtained after rosetting the
BM-LAM cell line using an anti-human k antibody (Becton-
Dickinson, Milan, Italy) and Dynabeads (Dynal, Milan, Italy),
following the manufacturers’ instructions. This cell line did not
have c-myc re-arrangements and therefore was considered a nor-
mal lymphoblastoid, EBV1 cell line.
Detection of EBV-fused terminal fragments by Southern blot
Southern blot analysis for the EBV-fused termini was performed
on high m.w. DNA (20 mg) after digestion with the BamHI
restriction enzyme (Boehringer-Mannheim, Mannheim, Germa-
ny). The XhoI 1.9 probe, which detects a DNA sequence adjacent
to right terminal repeat sequences of the viral genome (Raab-Traub
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and Flynn, 1986), was labeled with digoxigenin-11-dUTP by nick
translation following the instructions of the manufacturer (Boe-
hringer-Mannheim). Filters were hybridized to the digoxigenin-la-
beled probe overnight at 42°C in 50% formamide solution and
washed at high stringency (0.1 3 SSC/0.1% SDS, 65°C). The chemi-
luminescent signal produced by the hybridized probe was detected as
suggested by the manufacturer. Briefly, after hybridization, the filter
was subjected to immunological detection using an alkaline phospha-
tase (AP)–conjugated anti-digoxigenin antibody, diluted 1:5,000, and
then incubated in freshly prepared chemiluminescent AP substrate
solution at 0.25 mM final concentration. The filter was exposed to
record the chemiluminescent signals.
Preparation of templates for PCR
Total RNA was isolated from the cell lines using RNA clean
(TIB Molecular Biology, Genoa, Italy) according to the manufac-
turer’s instructions. One microgram of RNA was reverse-tran-
scribed to cDNA using M-MLV reverse transcriptase (GIBCO
BRL Life Technologies, Milan, Italy) and an oligo-dT (16 mer)
primer. This reaction were carried out in 25 ml using 10 pmole of
the primer at 42°C for 1 hr. Genomic DNA was prepared from cell
lines using the QIAamp blood kit (Qiagen, Basel, Switzerland),
following the manufacturer’s instructions.
Conditions for PCR and cDNA sequencing
To determine the Ig VH and VL gene nucleic acid sequences of
the cell lines, 2 ml of cDNA were amplified using a sense (VH or
VL) leader family-specific primer in conjunction with an anti-sense
Cm, Ck or Cl primer (Fais et al., 1999). PCR conditions have been
previously reported (Fais et al., 1999). PCR products were cloned
into TA vector (Invitrogen, San Diego, CA), and at least 4 different
molecular clones were sequenced for every LAM cellular clone
using an automated sequenator (Applied Biosystems, Milan, Italy).
The c-myc re-arrangement was amplified using 0.5 mg DNA.
The JHC primer CTG AGG AGA CGG TGA CCG TGG T was
used in conjunction with the c-myc 4839R primer CCA GCA GCT
CGG TCA CCA TCT C under the following conditions: denatur-
ation at 94°C for 20 sec, annealing and extension at 68°C for 2
min; after 30 cycles, extension was continued at 72°C for an
additional 10 min. rTth DNA polymerase (Perkin-Elmer, Milan,
Italy) was used. PCR products, obtained from 2 independent tests
for each cellular clone, were directly sequenced.
Analyses of Ig VH and VL sequences
Ig VH and VL sequences were compared with the V BASE
sequence directory (MRC Centre for Protein Engineering, Cam-
bridge, UK) using MacVector 6.0.1 software (Oxford Molecular
Group, Oxford, UK). To evaluate the distribution of mutations
among complementary determining region (CDR) and framework
(FR) gene segments, the Chang-Casali binomial distribution model
was used (Chang and Casali, 1994; details reported in Fais et al.,
1999).
Functional assay for p53 mutations
We evaluated the presence of functional p53 mutations in the
different cell lines by the yeast-based p53 functional assay devel-
oped by Flaman et al. (1995). In this assay, yeast colonies that
contain wild-type p53 are white, while colonies that contain mu-
tated p53 are red. Briefly, cDNA was synthesized from LAM-K,
BM-C4 and PB-D8 cell lines as reported above. The p53 open
reading frame between nucleotide positions 125 and 1122, includ-
ing all sequence coding for the DNA-binding domain of the
protein, was PCR-amplified using P3 and P4 primers and Vent
DNA polymerase (New England Biolabs, Milan, Italy) and 2 ml of
the cDNA reaction product for 35 cycles of 94°C for 30 sec, 65°C
for 60 sec and 78°C for 80 sec. To test the cDNA p53 status, PCR
products and HindIII-StuI–linearized pRDI-22, lacking the se-
quences coding for the entire p53 DNA-binding domain, were
co-transformed by electroporation into the haploid strain yIG397
(MATa ade2-1 leu2-3,112 trp1-1 his3-11,15 can1-100, ura3-1
URA3 3xRGC::pCYC1::ADE2) containing the ADE2 reporter
gene under p53 control. pRDI-22 was obtained from the yeast
expression vector of human wild-type p53 pLS76 (Ishioka et al.,
1993), containing LEU2 as the selectable marker in yeast cells, by
BsmI(4432)/StuI(3589) digestion. The HindIII-StuI–digested,
pRDI-22–gapped plasmid has 2 regions homologous to the termi-
nal regions of the PCR products obtained using P3 and P4. After
co-transfection followed by homologous recombination in vivo
(gap repair), a p53 expression vector having the wild-type pro-
moter region (derived from pRDI-22) and the core region of the
p53 open reading frame (derived from the P3/P4 PCR product)
was reconstituted. If the clone was initially ade- due to a mutation
in the promoter region, the gap-repaired transformants result in
almost exclusively white, normally sized colonies on limiting
adenine plates (no small red colonies) since the promoter in the
gap-repaired plasmid, derived from pRDI-22, is wild-type (gap
repair-negative). On the contrary, if the PCR product contained a
single mutation in the core region, approximately 100% of the
derived transformed clones gave rise to small red colonies (gap
repair-positive) (Flaman et al., 1995). p53 mutants, giving about
100% red colonies (gap repair-positive), were re-amplified and
sequenced as previously described (Inga et al., 1997).
Gap-repaired transformants were selected on minimal plates
lacking leucine but containing sufficient adenine (5 mg/ml) for
adenine auxotrophs to grow and turn red. The percentage of small
red colonies was determined. Eleven independent red clones (6
LAM-C4, 5 LAM-D8) were picked, grown overnight in synthetic
minimal medium lacking leucine but containing an excess of
adenine (200 mg/ml). pLS76 plasmids were recovered and the p53
cDNA were re-amplified with P3 and P4 primers and Taq DNA
polymerase (Promega, Florence, Italy). PCR products were puri-
fied by Microcon 100 (Amicon, Rho, Italy) and directly sequenced.
In addition to P3 and P4, 2 internal primers were used for sequenc-
ing: P5 59-TggCCATCTACAAgCAgTCA-39, nucleotides 479–
497, and P6 59-gggCACCACCACACTATgTC-39, nucleotides
638–657, of the p53 cDNA.
RESULTS
Ig VH gene-sequence analyses
Five clones from the PB-LAM cell line and 5 clones from the
BM-LAM cell line were utilized. These 2 groups of clones had the
same VDJ and c-myc re-arrangements but different EBV-fused
termini (Fig. 1) (Roncella et al., 1993). Re-arranged VH gene
FIGURE 1 – Southern blot of EBV-fused termini of LAM-derived
cell clones. BM-H4 and BM-C4 are 2 representative clones derived
from the bone marrow; PB-D8 and PB-2.1 are 2 representative clones
derived from the peripheral blood of the patient LAM. Peripheral
blood mononuclear cells (PBMCs) were used as negative control, and
a cell line originated following infection with B95.8 supernatant was
used as polyclonal control. MW, molecular weight.
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segments were amplified from each clone and sequenced. All
clones expressed the VH4–34 gene, the 3–9 D segment (also
known as DXP1) and the JH4 segment. However, despite extensive
analysis (40 molecular clones were analyzed), intra-clonal diver-
sification was never observed. The VH4–34 gene expressed by
LAM clones was extensively mutated (n 5 24, 8%; Fig. 2); there
was no statistical evidence for the accumulation of replacement
mutations in the CDR based on Chang-Casali criteria (p . 0.05),
though there was evidence for preservation of FR regions accord-
ing to the same criteria (p , 0.05).
Ig VL gene-sequence analysis
LAM cell lines and clones invariably expressed monotypic
IgM/l molecules when analyzed by immunofluorescence (Ron-
cella et al., 1993). When l light-chain cDNA was amplified from
4 clones (BM-D4, BM-H4, PB-D8 and PB-B2.1) and analyzed, all
clones invariably expressed the lv318 gene of the V l 3 family.
This gene was virtually germline (Fig. 2).
Previous Southern blot analyses revealed that the k locus of all
LAM cell lines presented 1 deleted and 1 re-arranged allele each
(Roncella et al., 1993). Indeed, RT-PCR disclosed that a k chain
transcript was present in all clones studied. Sequence analysis of
PCR products from 4 clones (BM-D4, BM-H4, PB-D8 and PB-
B2.1) showed that the Vk gene used by all of them was the B1
gene, which belongs to the VKVII family. This gene was origi-
nally described as being non-functional because of a nucleotide
change in the ATG starting codon (ATG3ATA) (Lorenz et al.,
1988); this nucleotide change was also present in LAM cells (not
shown). However, the gene differed from the B1 germline coun-
terpart by the presence of 12 somatic mutations (3.7%, Fig. 2). In
addition to the mutation in the starting codon, the Vk-Jk re-
arrangement in LAM cells generated an out-of-frame sequence
that completely excluded the possibility that the k gene could
encode a functional K chain.
Translocated c-myc sequence
Taking advantage of preliminary Southern blot studies (Saglio
et al., 1993), we designed a PCR approach to amplify and se-
quence the region encompassing the c-myc translocation (Fig. 3).
A JH primer was used in conjunction with a primer mapping to the
second exon of c-myc. A PCR product of about 1,700 bp was
amplified from BM-C4 and PB-D8 malignant clones, while no
product was obtained using the LAM-K lymphoblastoid B-cell line
(not shown). Sequence analysis disclosed that the c-myc break-
point was located at nucleotide 3170 juxtaposed to the JH6 seg-
ment (Fig. 4). There was no evidence for N-segment additions. As
shown in Figure 3, myc intron factors 1 and 2 were lost whereas
myc intron factor 3 was partially preserved; this finding is similar
to a previous report (Yu et al., 1993).
The translocated c-myc sequence had 7 nucleotide substitutions
in the first intron and 3 mutations in the portion of the second exon
analyzed (Fig. 4). These substitutions were present in both of the
clones analyzed and absent in LAM-K cells, thus indicating that
they were somatic mutations rather then allelic variants. In the
second exon, replacement mutations were present at codon 9
(AAc3AAg, Asn3Lys), codon 11 (AaC3AgC, Asn3Ser) and
codon 58 (AcC3AaC, Thr3Asn).
p53 analysis
The p53 functional assay (Flaman et al., 1995) was employed to
determine whether 2 representative clones, each from 1 group with
different EBV-fused termini, had p53 mutations capable of im-
pairing its function. p53 cDNAs, derived from different cells
(LAM-K, BM-C4 and PB-D8 cell clones), were PCR-amplified
and analyzed by gap repair in yeast. In detail, unpurified PCR
products were co-transfected with HindIII-StuI–linearized
pRDI-22 plasmid. HindIII-StuI–linearized pRDI has 2 regions
homologous to the terminal regions of the PCR products. After
co-transfection followed by homologous recombination in vivo
(gap repair), a p53 expression vector having the wild-type pro-
moter region (derived from pRDI-22) and the core region of the
p53 open reading frame (derived from the PCR product) was
reconstituted. If the PCR product contained a mutation, the recon-
stituted expression vector expressed a mutant p53 protein, unable
to transactivate the ADE2 reporter gene. In this assay, yeast col-
onies expressing such a mutant p53 originate small red colonies,
FIGURE 2 – Nucleotide sequences of re-arranged LAM Ig V genes. Nucleotide sequence of the LAM Ig V genes is shown and compared to
the corresponding germline Ig V sequence. CDRs are underlined.
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while colonies expressing wild-type p53 originate normally sized
white colonies. Both neoplastic cell clones (BM-C4 and PB-D8)
expressed completely inactive p53 alleles (near 100% red colo-
nies) (Table I), while the non-neoplastic LAM-K cell line ex-
pressed wild-type p53 alleles. This result is compatible with either
the presence in BM-C4 and PB-D8 cell clones of 2 alleles with
inactivating mutations or the presence of a single mutated allele
accompanied by loss of the other allele.
To determine whether BM-C4 and PB-D8 cells shared the same
p53 mutations, plasmids containing mutated p53 cDNA from 11
independent red yeast colonies (6 from BM-C4, 5 from PB-D8)
were rescued and sequenced (Table II). A C3T transition at
codon 273 resulting in an arginine to cysteine amino acid substi-
tution was present in 5 of 6 BM-C4 yeast colonies and in 3 of 5
PB-D8 yeast colonies. Three yeast colonies (BM-C4-8, PB-D8-4
and PB-D8-5) exclusively showed an insertion of 9 bp, resulting in
the insertion of 3 amino acids. One yeast colony derived from each
of the cell clones (BM-C4-2 and PB-D8-8) showed the co-exis-
tence of both mutations (C3T and 19 bp), most likely derived
from PCR cross-over. Therefore, at this level of analysis, the
BM-C4 and PB-D8 neoplastic cell clones appeared to have the
same 2 mutated alleles.
DISCUSSION
All of the cytogenetic changes observed in LAM cells took
place prior to EBV infection. Moreover, we have disclosed a
number of stepwise changes that potentially occurred during lym-
phomagenesis. Figure 5 schematically summarizes a hypothetical
cascade of events that contribute to the genesis of BL.
The VH gene used by LAM cells was 4–34, which contained
somatic mutations (Fig. 2) that failed to alter the FR regions of the
Ig molecule, suggesting antigen stimulation. This observation is
similar to that described previously in 2 other BLs that used the
same VH gene (Riboldi et al., 1994). Moreover, as in the cases
reported by Riboldi et al. (1994), the Ig produced by LAM cells
had cold agglutinin (CA) activity with specificity for the i antigen
present on the fetal red blood cells and not for the I antigen
expressed by erythrocytes from adults (data not shown). In anti-
bodies encoded by the VH4–34 gene, the i/I binding capacities are
determined primarily by the FR1 structure, while sequences of
HCDR3 dictate the fine specificity for either i or I (Li et al., 1996).
Although with CA, antigen binding is determined mainly by the H
chain, the L chain is also important since the presence of incom-
patible light chains abrogates antigen binding. Based on the pres-
ervation of FR regions, in particular FR1, and the choice of a
compatible l chain (see below), it appears likely that stimulation
by a carbohydrate structure related to the i antigen, which is not
expressed exclusively by red blood cells (Bhat et al., 1993; Grillot-
Courvalin et al., 1992), may play a role at a certain point during
lymphomagenesis. Whether this stimulation occurred concomi-
tantly with that of the specific antigen that also caused accumula-
tion of point mutations in the VH chain genes is unclear.
The sequence of the re-arranged Vl gene showed that it be-
longed to Vl3 family. In contrast with the re-arranged VH gene,
this gene was minimally mutated. Moreover, N additions were not
obvious at the Vl–Jl junction (Fig. 2). The virtual absence of
somatic mutations on the Vl gene suggests that this re-arrange-
ment was a relatively late event that took place in a k-expressing
cell after it had reached the GC and accumulated VH gene muta-
tions. Expression of RAG1 and RAG2 has been shown in human
GCs (Meffre et al., 1998; Giachino et al., 1998). This finding,
although somewhat debated based on observations of experimental
animals (Monroe et al., 1999; Yu et al., 1999), has been used to
suggest that this mechanism contributes to “antibody diversifica-
tion” and/or rescue of B cells with deleterious mutations on Ig V
genes (Rajewsky, 1998).
Although the clones expressed a monotypic l light chain, we
were able to amplify a re-arranged k gene in all of the LAM
clones. Sequencing the PCR product revealed that the re-arrange-
ment was non-productive due to frameshift mutations in the CDR3
region. Moreover, the Vk gene re-arranged was the B1 gene, the
unique member of the VKVII family which is non- functional
because of a mutation in the ATG starting codon (Lorenz et al.,
1988). The timing of the k chain re-arrangement could not be
determined precisely, though the presence of a significant number
of somatic mutations suggests that it took place before the Vl gene
re-arrangement. The other k allele was deleted (Roncella et al.,
1993), a finding that makes analyses of molecular events in LAM
cells more complicated. One possible explanation, based on the
non-functional re-arrangement of the remaining k allele and its
mutation pattern, is that the deleted k gene was indeed the one used
by the clone to code for the Ig molecules, potentially up to their
transit in the GC. There, both productive and non-productive Vk
genes were likely to accumulate point mutations before deletion of
the productive k allele and the switch to the l light chain. A similar
example of the Ig V light-chain switch has been reported in a
FIGURE 3 – Schematic representation of PCR strategy used to amplify re-arranged c-myc in LAM cells, with the breakpoint on the c-myc gene
anf some relevant features indicated. Upper figure represents the c-myc gene juxtaposed to the Ig heavy-chain region as deduced by nucleotide
sequence of the region encompassing the re-arrangement. JHC and c-myc 4839 were the primers used for PCR amplification. In the lower figure,
the c-myc breakpoint is shown in relationship to myc intron factor (MIF) regions. P1 and P2 indicate promoters present in the first intron. 3170,
nucleotide number of the breakpoint (refers to submitted c-myc sequence X00364).
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normal B cell line derived from peripheral blood (de Wildt et al.,
1999).
The re-arranged c-myc gene was amplified and sequenced in 2
representative clones, from PB and BM (PB-D8 and BM-H4), with
different EBV-fused termini. The sequences did not differ between
the 2 clones. Ten nucleotide substitutions were observed in the
amplified segment. Interestingly, replacement mutations in the
second exon were present at codons 9, 11 and 58. This area
encodes the N-terminal transcription activation domain (Henriks-
son and Luscher, 1996). In particular, Thr58 and other amino acids
in its proximity have been described as often being targeted by
somatic mutations in the re-arranged c-myc allele in BL (Bhatia et
al., 1994). Moreover, phosphorylation of Thr58 is necessary for the
c-myc–suppressing activity of p107, a protein related to the reti-
noblastoma protein. The lack of Thr58 phosphorylation results in
increased transforming activity in vitro (Hoang et al., 1995), likely
due to decreased proteasome-mediated turnover (Bahram et al.,
2000). Therefore, these changes may have contributed to further
acquisition of malignant properties by LAM cells. The translocated
c-myc oncogene was likely to have mutated during cell passage in the
GC because of the proximity of the Ig genes. Whether translocation of
c-myc also took place at the same site could not be determined, though
the occurrence of recombination events, including isotype switching
and possibly secondary Ig gene re-arrangements, makes this hypoth-
esis particularly appealing (Kuppers et al., 1999).
Sequence and functional analyses showed that both p53 alleles
from malignant LAM cells carried mutations resulting in protein
inactivation. These mutations were somatically acquired and
FIGURE 4 – Nucleotide sequence of region encompassing the c-myc re-arrangement on Ig heavy-chain locus on chromosome 14 in LAM cells.
Underlined sequences at top and bottom represent primer areas. Preserved portion of myc intron factor 3 is highlighted. The ATG starting codon
(at position 4522) is highlighted. The 3 mutated codons in the c-myc coding region are underlined.
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present in both groups of clones with different EBV-fused termini.
The timing of these mutations could not be ascertained. However,
the involvement of p53 in inducing apoptosis (Liebermann et al.,
1995) and the abundant evidence demonstrating that c-myc over-
expression predisposes cells to apoptosis (Cutrona et al., 1995;
Polack et al., 1996). Hence, it is possible that p53 mutations
favored the expansion of cells that already had a translocated
c-myc.
The presence of multiple EBV-fused termini is generally taken
as evidence for multiple infection events (Raab-Traub and Flynn,
1986), though alternative explanations have been offered, includ-
ing recombination among EBV episomes. These may be used to
explain the heterogeneity of EBV-fused termini in certain, other-
wise monoclonal, tumor samples taken ex vivo (Delecluse et al.,
1993) since EBV recombination may occur in some cellular com-
ponents of a given malignant clone. Following this event, because
of the presence of a multiplicity of EBV copies, the malignant cells
would display a combination of original as well as recombinant
EBV termini. In LAM cells, however, cellular clones could be
isolated with single, albeit different, EBV-fused termini. Subse-
quent infectious events, rather than recombination of episomes,
perhaps best explain this finding.
Collectively, the above data reiterate the notion that in AIDS-
related BL EBV infection represents a late event in cells that
have already accumulated a number of cytogenetic changes
(Roncella et al., 1993; Gutierrez et al., 1997). This observation
raises a number of questions related to both the promoting
factors that facilitate the clonal expansion of malignant B
lymphocytes as well as the role of EBV in the pathogenesis of
lymphoma. Although these questions remain unresolved, it is
tempting to speculate that stimulation by specific antigens or
even by a superantigen represents an important promoting ef-
fect on transforming B cells, at least until their entrance into the
GC, where c-myc translocation may occur. As for the pathoge-
netic role of EBV, doubts may be raised primarily by the
observation that in AIDS-related BL, as well as in other BL
cases, type I latency of the virus occurs (Rowe et al., 1986).
With this type of latency, which was also observed in LAM
cells (Roncella et al., 1993), EBNA2 or EBNA3 antigens are
not expressed and, hence, cannot promote cell proliferation. Likewise
LMP1, which prevents apoptosis (Henderson et al., 1991; Wang et
al., 1987, 1990), is absent. However, EBNA1, which is consistently
expressed by these BL cells, can have a promoting role in lym-
phomagenesis (Wilson et al., 1996). This concept is also supported by
our previous observation that all LAM cells invariably expressed
EBV (Roncella et al., 1993), indicating that the presence of the virus
provided a growth advantage.
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TABLE I – ANALYSIS OF p53 Status in the Different Cell Lines
by Yeast Functional Assay
Colonies
Colonies
Red total (%)
Red White
Control 149 540 21.6
LAM-K 246 854 22.4
BM-C4 2,965 92 97.01
PB-D8 1,578 37 97.71
As control, pLS76 expression plasmid containing wild-type p53
cDNA was PCR-amplified using primers P3 and P4 and Vent DNA
polymerase.–1p , 0.0001 (x2 test, compared to control).
TABLE II – SEQUENCING ANALYSIS ON INDEPENDENT p53 Mutant Clones
Arg273.Cys 9 bp Insertion1
BM-C4-1 1 2
BM-C4-2 1 1
BM-C4-5 1 2
BM-C4-6 1 2
BM-C4-7 1 2
BM-C4-8 2 1
PB-D8-2 1 2
PB-D8-4 2 1
PB-D8-5 2 1
PB-D8-7 1 2
PB-D8-8 1 1
1The 96p, in-frame insertion (sequence GGG TGT AAC) coding for
Gly-Cys-Asn occurred between codon 239 and codon 240.
FIGURE 5 – Schematic representation of factors possibly involved in AIDS-related BL pathogenesis. Antigen (or superantigen-like molecules,
such as i antigen) drives initial expansion of a certain number of B-cell clones (oligoclonal expansion). One of these clones accumulates a number
of cytogenetic changes possibly related to the other molecular events occurring in the GC (somatic hypermutation, Ig isotype switch and receptor
editing). p53-inactivating mutations appear to be necessary for survival of these cells. Whether mutations of p53 occur during the transit of GC
or outside the GC is not known. Heterogeneity of EBV-fused termini in neoplastic cells suggests that EBV infection is a late event and might
contribute to malignancy in immunocompromised subjects.
749GENETIC CHANGES IN BL
REFERENCES
BAHRAM, F., VON DER LEHR, N., CETINKAYA, C. and LARSSON, L.G., c-Myc
hot spot mutations in lymphomas result in inefficient ubiquitination and
decreased proteasome-mediated turnover. Blood, 95, 2104–2110 (2000).
BHAT, N.M., BIEBER, M.M., CHAPMAN, C.J., STEVENSON, F.K. and TENG,
N.N., Human antilipid A monoclonal antibodies bind to human B cells and
the i antigen on cord red blood cells. J. Immunol., 151, 5011–5021 (1993).
BHATIA, K., SPANGLER, G., GAIDANO, G., HAMDY, N., DALLA FAVERA, R.
and MAGRATH, I., Mutations in the coding region of c-myc occur frequently
in acquired immunodeficiency syndrome-associated lymphomas. Blood,
84, 883–888 (1994).
CAPELLO, D., CARBONE, A., PASTORE, C., GLOGHINI, A., SAGLIO, G. and
GAIDANO, G., Point mutations of the BCL-6 gene in Burkitt’s lymphoma.
Brit. J. Haematol., 99, 168–170 (1997).
CHANG, B. and CASALI, P., The CDR1 sequences of a major proportion of
human germline Ig VH genes are inherently susceptible to amino acid
replacement. Immunol. Today, 15, 367–373 (1994).
CROCE, C.M., THIERFELDER, W., ERIKSON, J., NISHIKURA, K., FINAN, J., LENOIR,
G.M. and NOWELL, P.C., Transcriptional activation of an unre-arranged and
untranslocated c-myc oncogene by translocation of a C lambda locus in
Burkitt. Proc. nat. Acad. Sci. (Wash.), 80, 6922–6926 (1983).
CUTRONA, G., ULIVI, M., FAIS, F., RONCELLA, S. and FERRARINI, M.,
Transfection of the c-myc oncogene into normal Epstein-Barr virus-har-
boring B cells results in new phenotypic and functional features resembling
those of Burkitt lymphoma cells and normal centroblasts. J. exp. Med., 181,
699–711 (1995).
DALLA-FAVERA, R., BREGNI, M., ERIKSON, J., PATTERSON, D., GALLO, R.C.
and CROCE, C.M., Human c-myc onc gene is located on the region of
chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. nat.
Acad. Sci. (Wash.), 79, 7824–7827 (1982).
DELECLUSE, H.J., RAPHAEL, M., MAGAUD, J.P., FELMAN, P., ALSAMAD, I.A.,
BORNKAMM, G.W. and LENOIR, G.M., Variable morphology of human
immunodeficiency virus–associated lymphomas with c-myc re-arrange-
ments. Blood, 82, 552–563 (1993).
DE WILDT, R.M., HOET, R.M.A., VAN VENROOIJ, W.J., TOMLINSON, I.M. and
WINTER, G., Analysis of heavy and light chain pairings indicates that
receptor editing shapes the human antibody repertoire. J. mol. Biol., 285,
895–901 (1999).
FAIS, F., GAIDANO, G., CAPELLO, D., GLOGHINI, A., GHIOTTO, F., RONCELLA,
S., CARBONE, A., CHIORAZZI, N. and FERRARINI, M., Immunoglobulin V
region gene use and structure suggest antigen selection in AIDS-related
primary effusion lymphomas. Leukemia, 13, 1093–1099 (1999).
FLAMAN, J.M., and 13 OTHERS, A simple p53 functional assay for screening cell
lines, blood, and tumors. Proc. nat. Acad. Sci. (Wash.), 92, 3963–3967 (1995).
GAIDANO, G., BALLERINI, P., GONG, J.Z., INGHIRAMI, G., NERI, A., NEW-
COMB, E.W., MAGRATH, I.T., KNOWLES, D.M. and DALLA-FAVERA, R., p53
mutations in human lymphoid malignancies: association with Burkitt lym-
phoma and chronic lymphocytic leukemia. Proc. nat. Acad. Sci. (Wash.),
88, 5413–5417 (1991).
GAIDANO, G. and DALLA-FAVERA, R., Molecular pathogenesis of AIDS-
related lymphomas. Adv. Cancer Res., 67, 113–153 (1995).
GIACHINO, C., PADOVAN, E. and LANZAVECCHIA, A., Re-expression of
RAG-1 and RAG-2 genes and evidence for secondary re-arrangements in
human germinal center B lymphocytes. Europ. J. Immunol., 28, 3506–
3513 (1998).
GRILLOT-COURVALIN, C., BROUET, J.C., PILLER, F., RASSENTI, L.Z., LA-
BAUME, S., SILVERMAN, G.J., SILBERSTEIN, L. and KIPPS, T.J., An anti-B cell
autoantibody from Wiskott-Aldrich syndrome which recognizes i blood
group specificity on normal human B cells. Europ. J. Immunol., 22,
1781–1788 (1992).
GUTIERREZ, M., BHATIA, K., CHERNEY, B., CAPELLO, D., GAIDANO, G. and
MAGRATH, I., Intraclonal molecular heterogeneity suggests a hierarchy of
pathogenetic events in Burkitt’s lymphoma. Ann. Oncol., 8, 987–994 (1997).
HENDERSON, S., ROWE, M., GREGORY, C., CROOM-CARTER, D., WANG, F.,
LONGNECKER, R., KEIFF, E. and RICKINSON, A., Induction of bcl-2 expres-
sion by Epstein-Barr virus latent membrane protein 1 protects infected B
cells from programmed cell death. Cell, 65, 1107–1115 (1991).
HENRIKSSON, M. and LUSCHER, B., Proteins of the Myc network: essential
regulators of cell growth and differentiation. Adv. Cancer Res., 68, 109–
182 (1996).
HOANG, A., LUTTERBACH, B., LEWIS, B.C., YANO, T., CHOU, T.Y., BAR-
RETT, J.F., RAFFELD, M., HANN, S.R. and DANG, C.V., A link between
increased transforming activity of lymphoma-derived MYC mutant alleles,
their defective regulation by p107, and altered phosphorylation of the
c-Myc transactivation domain. Mol. cell. Biol., 15, 4031–4042 (1995).
INGA, A., CRESTA, S., MONTI, P., APRILE, A., SCOTT, G., ABBONDANDOLO, A.,
IGGO, R. and FRONZA, G., Simple identification of dominant p53 mutants by a
yeast functional assay. Carcinogenesis, 18, 2019–2021 (1997).
ISHIOKA, C., FREBOURG, T., YAN, Y.X., VIDAL, M., FRIEND, S.H., SCHMIDT,
S. and IGGO, R., Screening patients for heterozygous p53 mutations using
a functional assay in yeast. Nature (Genet.), 5, 124–129 (1993).
KUPPERS, R., KLEIN, U., HANSMANN, M.L. and RAJEWSKY, K., Cellular origin
of human B-cell lymphomas. N. Engl. J. Med., 341, 1520–1529 (1999).
LI, Y., SPELLERBERG, M.B., STEVENSON, F.K., CAPRA, J.D. and POTTER,
K.N., The I binding specificity of human VH 4-34 (VH 4-21) encoded
antibodies is determined by both VH framework region 1 and complemen-
tarity determining region 3. J. mol. Biol., 256, 577–589 (1996).
LIEBERMANN, D.A., HOFFMAN, B. and STEINMAN, R.A., Molecular controls
of growth arrest and apoptosis: p53-dependent and independent pathways.
Oncogene, 11, 199–210 (1995).
LORENZ, W., SCHABLE, K.F., THIEBE, R., STAVNEZER, J. and ZACHAU, H.G.,
The J kappa proximal region of the human K locus contains three uncom-
mon V kappa genes which are arranged in opposite transcriptional polar-
ities. Mol. Immunol., 25, 479–484 (1988).
MAGRATH, I., The pathogenesis of Burkitt’s lymphoma. Adv. Cancer Res.,
55, 133–270 (1990).
MEFFRE, E., PAPAVASILIOU, F., COHEN, P., DE BOUTEILLER, O., BELL, D.,
KARASUYAMA, H., SCHIFF, C., BANCHEREAU, J., LIU, Y.J. and NUSSENZWEIG,
M.C., Antigen receptor engagement turns off the V(D)J recombination
machinery in human tonsil B cells. J. exp. Med., 188, 765–772 (1998).
MONROE, R.J., SEIDL, K.J., GAERTNER, F., HAN, S., CHEN, F., SEKIGUCHI, J.,
WANG, J., FERRINI, R., DAVIDSON, L., KELSOE, G. and ALT, F.W., RAG2:
GFP knockin mice reveal novel aspects of RAG2 expression in primary
and peripheral lymphoid tissues. Immunity, 11, 201–212 (1999).
POLACK, A., HORTNAGEL, K., PAJIC, A., CHRISTOPH, B., BAIER, B., FALK,
M., MAUTNER, J., GELTINGER, C., BORNKAMM, G.W. and KEMPKES, B.,
c-myc activation renders proliferation of Epstein-Barr virus (EBV)–trans-
formed cells independent of EBV nuclear antigen 2 and latent membrane
protein 1. Proc. nat. Acad. Sci. (Wash.), 93, 10411–10416 (1996).
RAAB-TRAUB, N. and FLYNN, K., The structure of the termini of the
Epstein-Barr virus as a marker of clonal cellular proliferation. Cell, 47,
883–889 (1986).
RAJEWSKY, K., Burnet’s unhappy hybrid. Nature (Lond.), 394, 624–625
(1998).
RIBOLDI, P., GAIDANO, G., SCHETTINO, E.W., STEGER, T.G., KNOWLES,
D.M., DALLA-FAVERA, R. and CASALI, P., Two acquired immunodeficiency
syndrome–associated Burkitt’s lymphomas. Blood, 83, 2952–2961 (1994).
RONCELLA, S., DI CELLE, P.F., CUTRONA, G., CARBONE, A., SESSAREGO, M.,
LANDONIO, G., FOA, R., ROWE, M. and FERRARINI, M., Cytogenetic re-
arrangement of C-MYC oncogene occurs prior to infection with Epstein-
Barr virus in the monoclonal malignant B cells from an AIDS patient.
Leukemia Lymphoma, 9, 157–164 (1993).
ROWE, D.T., ROWE, M., EVAN, G.I., WALLACE, L.E., FARRELL, P.J. and
RICKINSON, A.B., Restricted expression of EBV latent genes and T-lym-
phocyte-detected membrane antigen in Burkitt’s lymphoma cells. EMBO
J., 5, 2599–2607 (1986).
SAGLIO, G. and 13 OTHERS, Preferential clustering of chromosomal break-
points in Burkitt’s lymphomas and L3 type acute lymphoblastic leukemias
with a t(8;14) translocation. Genes Chromosomes Cancer, 8, 1–7 (1993).
WANG, F., GREGORY, C., SAMPLE, C., ROWE, M., LIEBOWITZ, D., MURRAY,
R., RICKINSON, A. and KIEFF, E., Epstein-Barr virus nuclear antigen 2
specifically induces expression of the B-cell activation antigen CD23.
Proc. nat. Acad. Sci. (Wash.), 84, 3452–3456 (1987).
WANG, F., GREGORY, C.D., ROWE, M., RICKINSON, A.B., WANG, D.,
BIRKENBACH, M., KIKUTANI, H., KISHIMOTO, T. and KIEFF, E., Epstein-Barr
virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are
effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1
cooperatively induce CD23. J. Virol., 64, 2309–2318 (1990).
WILSON, J.B., BELL, J.L. and LEVINE, A.J., Expression of Epstein-Barr virus
nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J.,
15, 3117–3126 (1996).
YU, B., ICHINOSE, I., BONHAM, M.A. and ZAJAC KAYE, M., Somatic muta-
tions in c-myc intron I cluster in discrete domains that define protein
binding sequences. J. biol. Chem., 268, 19586–19592 (1993).
YU, W., NAGAOKA, H., JANKOVIC, M., MISULOVIN, Z., SUH, H., ROLINK, A.,
MELCHERS, F., MEFFRE, E. and NUSSENZWEIG, M.C., Continued RAG
expression in late stages of B cell development and no apparent re-
induction after immunization. Nature (Lond.), 400, 682–687 (1999).
750 FAIS ET AL.
